Dr. Helen J. Ross, MD

Dr. Ross practices at Rush University Medical Center in Chicago, Illinois, part of Rush System for Health.

Dr. Ross' NPI, 1841282159, was assigned on August 22, 2005. Dr. Ross graduated from David Geffen School of Medicine at UCLA in 1984. Dr. Ross holds Illinois license 036164755.

Dr. Ross' primary practice is Rush University Medical Center, at 1653 West Congress Parkway, Chicago, IL 60612 in Cook County. The practice phone is (312) 942-5000.

Dr. Ross' primary practice is Rush University Medical Center in Chicago, Illinois, part of Rush System for Health. The medical group on file is Rush University Medical Center. Dmand AI also links Dr. Ross to 1 more group practice or clinic, 1 ambulatory surgery center and 1 medical group, each named with a free account. Dr. Ross' employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Ross practices, 3 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Ross' primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Ross is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Ross' licenses on file in 5 states: Illinois, Arizona, California, Oregon and Colorado.

Dmand AI lists lung cancer among the conditions Dr. Ross treats.

CMS data shows 169 Medicare services from Dr. Ross across 3 procedure codes in 2024, for 35 Medicare patients. Medicare paid $13,164 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 35 Medicare patients who saw Dr. Ross in 2024. The largest group is 75 to 84, with 17 patients. 75% of them have cancer, and 75% have high blood pressure. Their average risk score is 2.17, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Ross' median patient age at 70, with 45% women.

In 2024, Dr. Ross wrote 75 Medicare Part D claims for 20 patients. 88% of them were for generic drugs. CMS names the drug for 27 of them, across 2 drugs with 11 or more claims each, at $646 in total drug cost. In 2023, CMS named 26 claims across 1 drug.

Dr. Ross accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Ross as offering telehealth.

Dmand AI links 66 papers to Dr. Ross, published from 2006 to 2022. 2016 was the busiest year, with 3. The most frequent topics are Lung Neoplasms, Antineoplastic Combined Chemotherapy Protocols and Carcinoma, Non-Small-Cell Lung. Dr. Ross has published most often in J Thorac Oncol. Dr. Ross' most frequent co-authors are Jonathan B. Ashman, MD, Corey J. Langer, MD and Steven E. Schild, MD.

Dmand AI links Dr. Ross to 8 clinical trials, 4 of them phase 2 studies. 1 is still active or recruiting. Conditions studied include Carcinoma, Non-Small-Cell Lung, Carcinoma, Bronchogenic and Adenocarcinoma of Lung. Alliance Foundation Trials, LLC. sponsors the most, 2.

CMS Open Payments shows 15 general payments to Dr. Ross from 8 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 94% of the total. Gilead Sciences, Inc. paid the most, $5,236. It also lists 2 research payments totaling $706 in 2020.

Dr. Ross graduated from David Geffen School of Medicine at UCLA in 1984. Dr. Ross is a member of AACR, ASTRO, ASCO and International Association for the Study of Lung Cancer.

Dr. Ross is in network with 12 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. Medicare plans come from the most carriers, 10. Check the plan with the practice before a visit.